Get the content you want anytime you want.
ID Week 2018

Select coverage from ID Week 2018 is included below:

Infectious Diseases and Transplantation—A Look Ahead
Taking a closer look at the infectious disease risks posed by transplantation and what the future might have in store as the scope of transplantation expands.
RESTORE-IMI 1 Trial Compares IMI/REL and IMI+CST in Patients with Bacterial Infections
Keith Kaye, MD, presented the analysis of the RESTORE-IMI 1 phase 3 trial which evaluated imipenem/cilastatin/relebactam versus imipenem/cilastatin plus colistin.
Zoonotic Transmission of the Hepatitis E Virus
Kenneth E. Sherman, MD discusses the zoonotic hepatitis E virus and about the first reported case of rat-to-human transmission.
Entering a New Era of Blood Culture Testing Technology
Melvin Weinstein, MD, discusses the current and emerging technologies for the laboratory diagnosis of bloodstream infections.
Phase 2 Trial Evaluates DAS181 for Parainfluenza Virus in Immunocompromised Patients
Roy Chemaly, MD, MPH discusses the findings of the phase 2 trial evaluating DAS181 for the treatment of parainfluenza virus lower respiratory tract infections in immunocompromised patients.
Treatment of Antibiotic-Resistant Infections: Back to the Future of Therapies
The stage may finally be set for the phage therapy era for recalcitrant bacterial infections.
The Benefits of Dual Therapy for Gram-Negative Infections: An Assessment of the Guidelines
Julie Ann Justo, PharmD, MS, BCPS-AQ ID, shares takeaways from her presentation on combination therapy for gram-negative agents at the 2018 SIDP Annual Meeting.
OPAT-Antimicrobial Stewardship Team Coordination Ideal For Improving Patient Outcomes Upon Readmission
Efforts such as improved indication documentation and antimicrobial stewardship involvement may improve patient outcomes in some patients who are on outpatient parenteral antimicrobial therapy (OPAT) for ease of administration (EOA) that are readmitted to the hospital.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?